Market Overview

UPDATE: Morgan Stanley Reiterates On Cardinal Health On Dublin Day Takeaways

Share:
Related CAH
Analyst: Cardinal Health Buying Spree To Boost FY17 EPS
Benzinga's Weekend M&A Chatter

In a report published Wednesday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating on Cardinal Health (NYSE: CAH), but removed the $76.00 price target.

In the report, Morgan Stanley noted, “Contribution from CVS JV should ramp through FY15 with benefit weighted towards 2H, reaching full run-rate in FY16. Lines between channels of trade will likely continue to blur as scale becomes most critical. Importantly the CVS JV provides manufacturers with access to 3 channels (retail, distributor, and mail). JV structure has been well received by existing customers. Longer term, as the gap between top 3-4 buyers and the rest widens, larger pharmacies likely to rethink existing self-warehousing generic strategy.”

Cardinal Health closed on Tuesday at $66.20.

Latest Ratings for CAH

DateFirmActionFromTo
Jun 2015Deutsche BankMaintainsHold
Mar 2015FBR CapitalMaintainsOutperform
Mar 2015Argus ResearchMaintainsBuy

View More Analyst Ratings for CAH
View the Latest Analyst Ratings

Posted-In: Morgan Stanley Ricky R. GoldwasserAnalyst Color Price Target Analyst Ratings

 

Related Articles (CAH)

Around the Web, We're Loving...

Get Benzinga's Newsletters